Search Results
Showing Results for lung diseases
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this Future Leaders interview, we speak with Dr Kaylee Worlock, post-doctoral research fellow at UCL and winner of the 2025 Rising Stars award at the 7th Forum on RTIs. Dr Worlock shares her journey into respiratory science, her pioneering work in developmental biology, and her vision for the future of translational research.
Future Leader, Dr Michelle Korah-Sedgwick discusses her innovative work at the intersection of immunology and respiratory care, focusing on uncovering immune deficiencies in chronic lung disease. She shares insights on personalized treatment approaches, the value of clinical vigilance, and how registries are transforming care for patients with complex respiratory conditions.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Dr. Véronique Suttels discusses her work on improving tuberculosis (TB) diagnostics in low-resource settings through AI-assisted lung ultrasound (LUS). In this Future Leaders interview, Dr Suttels outlines the potential challenges of implementing diagnostic tools like CAD LUS4TB across multiple countries and reflects on the role of technology in addressing diagnostic gaps. Her research highlights both the potential and limitations of AI in advancing equitable, scalable solutions for global TB control.
Improving Access and Outcomes in Pulmonary and Critical Care: A Q&A with Future Leader, Dr Amy Wolfe
As part of our Future Leaders series, we spoke with Dr Amy Wolfe, Director of the LSUHSC-Wetmore TB Clinic and Assistant Professor of Medicine at LSUHSC in New Orleans. A specialist in pulmonary and critical care medicine, Dr Wolfe shares how her early experiences in post-Katrina New Orleans inspired her focus on health equity. She discusses the challenges of treating TB in underserved communities, the importance of wraparound care, and promising innovations in pulmonology—from AI-based diagnostics to expanded access to pulmonary rehabilitation and lung cancer screening.
As part of our Future Leaders series, Dr Debasree Banerjee, Assistant Professor at Brown University, shares her journey in pulmonary and critical care medicine (PCCM), highlighting its dynamic, collaborative nature. Passionate about equity, her research addresses how race and racism impact care. Dr Banerjee emphasizes perseverance, multidisciplinary collaboration, and inspiring future physicians through advocacy and meaningful patient connections.
As part of our Future Leaders series, we speak with Dr Helen Gavillet, a post-doctoral researcher at Northumbria University (UK) and Rising Star at RTI 2025. Dr Gavillet's research focuses on the lung microbiome in cystic fibrosis, particularly bacterial and fungal dynamics. Her research also examines the impact of CFTR modulators like elexacaftor/tezacaftor/ivacaftor on respiratory microbiota.
As part of our Future Leaders series, Dr. Shelby MacRae, a pulmonary and critical care specialist at LSUHSC, shares her journey from ICU intern to bronchiectasis and NTM researcher. She discusses challenges in care, lack of awareness, and future advances. Passionate about mentorship, she encourages future pulmonologists to find balance, build foundations, and stay driven by patient needs.
The current treatment landscape for severe asthma faces major challenges despite biologic advances targeting type 2 inflammation. Current biomarkers like BEC and FeNO inadequately predict treatment response. To optimize precision medicine, improved molecular phenotyping and novel non-invasive biomarkers are urgently needed to better identify asthma endotypes and guide therapy.
In this episode, Professor Irene Higginson, Director of Better Health and Care Futures at King’s College London, discusses the complex challenges of managing breathlessness. She explores non-pharmacological strategies, the value of multidisciplinary care, and how the Breathlessness Support Services at KCL are transforming patient support. Tune in for expert insights and a look at future directions in breathlessness research and care.
In this interview, Professor Juzar Ali, MD, FRCP(C), FCCP, a leading expert in respiratory medicine and LSU Alumni Klein Professor Emeritus of Medicine at Louisiana State University (LSU) Health Sciences Center in New Orleans, LA, USA, reflects on his distinguished career specializing in tuberculosis (TB), non-tuberculous mycobacterial disease (NTM) and bronchiectasis.
Asthma affects nearly 300 million people worldwide.1Â Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2Â Climate change is also predicted ...
We are excited to welcome you to San Francisco for the ATS 2025 International Conference! Leaders, as well as emerging scientists and clinicians, who are at the forefront of medical breakthroughs and clinical innovation in pulmonary, critical care and sleep medicine will gather for networking and inspiring talks.
GSK has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application for depemokimab, an investigational monoclonal antibody targeting interleukin-5 (IL-5), for two indications: as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation characterized by an eosinophilic phenotype, and as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
As winter takes hold, the World Health Organisation (WHO) has begun sharing updates on pathogens and their impact across the Northern Hemisphere. This time of year is marked by a significant rise in acute respiratory infections (ARIs) and other common respiratory illnesses.
As 2024 comes to a close and as the new Patient Advisory Board & Advocacy Manager at EUFOREA, I have the privilege to reflect on the achievements and milestones of EUFOREA this year. With my background as a pharmacist and scientific ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
